The KD-CAAP Recruitment Deadline is 31-Jul-2024!


Number of Recruited Participants: 103

Last Updated: 11-Jul-2024

Kawasaki Disease Coronary Artery Aneurysm Prevention trial

A multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD)

Welcome to KD-CAAP

The website has been designed to provide information, news and updates on the KD-CAAP trial to participants, parents, carers, the public and trial collaborators.

KD-CAAP is aiming to determine whether adding immediate corticosteroid treatment to standard of care IVIG and aspirin will reduce coronary artery aneurysm (CAA) rates in unselected Kawasaki Disease (KD) patients across Europe compared with IVIG and aspirin alone.

Follow the links below or use the menu bar at the top of the page to find out more about the trial and its network collaboration.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No.777389.
The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.